Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
begelomab
- Development stage
- Phase 2
- Lead developer
- Adienne S.r.l. S.U.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Begelomab is a murine monoclonal antibody that targets dipeptidyl peptidase 4 (DPP4, also known as CD26), a protein expressed on T cells. By binding to CD26, begelomab inhibits T cell activation and proliferation, thereby suppressing immune responses implicated in diseases such as graft-versus-host disease (GvHD) and dermatomyositis. The drug acts as an immunosuppressant by blocking DPP4/CD26-mediated pathways involved in the expansion of autoreactive T cells. Begelomab has received orphan drug designation for GvHD and dermatomyositis and is being developed primarily by ADIENNE Pharma & Biotech[1][2][3][5][6].
- Brand names
- BegedinaBegesand
- Other names
- begelomabanti-CD26 begelomabanti-CD-26 begelomabanti-CD 26 begelomab
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on begelomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on begelomab.